Latest News

Latest News

Clinical Trials Roundup | 21 Aug 2026

Clinical Trials Roundup | 21 Aug 2026

Merck and Moderna’s intismeran autogene meets its primary endpoint in the Phase 3 INTerpath-001 trial in completely resected melanoma, Ultragenyx’s Genglycos receives FDA accelerated approval as the first treatment for glycogen storage disease type Ia, argenx’s...

read more

Join The Future Of Life Sciences Media

 

In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.

 

 

Don’t wait for the media to pick up your story. Be the media.

More News

Chinese Biotech Industry Shows No Signs of Slowing

Chinese Biotech Industry Shows No Signs of Slowing

The Chinese biotechnology sector continues to accelerate, signing high-value deals and expanding its global footprint even as the United States prepares new restrictions on collaborations and funding. Despite growing geopolitical tensions, China’s biopharma industry...

read more
Emerging Drug Therapies in the Fight Against Sarcopenia

Emerging Drug Therapies in the Fight Against Sarcopenia

Why Sarcopenia Matters Sarcopenia, the age-related decline in skeletal muscle mass and strength, has become a growing concern in ageing populations. The condition contributes significantly to frailty, falls, fractures, disability and even mortality, placing an...

read more
Navigating Life with Haemophilia with Pfizer

Navigating Life with Haemophilia with Pfizer

Life with haemophilia can be challenging but advances in science are helping people with haemophilia to lead active and fulfilling lives. What is Haemophilia? Haemophilia is a family of rare genetic blood disorders caused by a clotting factor deficiency, which...

read more
Chinese Biotech Industry Shows No Signs of Slowing

Chinese Biotech Industry Shows No Signs of Slowing

The Chinese biotechnology sector continues to accelerate, signing high-value deals and expanding its global footprint even as the United States prepares new restrictions on collaborations and funding. Despite growing geopolitical tensions, China’s biopharma industry...

read more
Emerging Drug Therapies in the Fight Against Sarcopenia

Emerging Drug Therapies in the Fight Against Sarcopenia

Why Sarcopenia Matters Sarcopenia, the age-related decline in skeletal muscle mass and strength, has become a growing concern in ageing populations. The condition contributes significantly to frailty, falls, fractures, disability and even mortality, placing an...

read more
Navigating Life with Haemophilia with Pfizer

Navigating Life with Haemophilia with Pfizer

Life with haemophilia can be challenging but advances in science are helping people with haemophilia to lead active and fulfilling lives. What is Haemophilia? Haemophilia is a family of rare genetic blood disorders caused by a clotting factor deficiency, which...

read more

Featured Articles

DNA double helix beside a microscope, test tubes and a pipette over a petri dish, representing life science publishing

Life Science Publishing: Our First Year, and Where You Fit In

Almost a year ago, Life Science Daily News published its first articles with a simple belief. Specialist science deserves a specialist stage. Since then, that belief has grown into a global readership and an active community of contributors. This is the story of our...
FDA building exterior alongside pharmaceutical laboratory setting representing drug approval decisions

FDA Drug Approval Decisions

Last updated 28 October 2026. Covering target action dates from October 2026 to February 2027. October changed how this tracker has to be read. Six FDA drug approval decisions landed in the month, and four arrived ahead of target. One cleared roughly 12 weeks early,...
gloved hands holding a glowing blue sample vial (labelled LOT: 24-B1, SAMPLE: GENO-) with a lab researcher working in the background.

CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune

CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
Three GLP-1 drug pipeline injection pens and oral tablets beside a clinical trial efficacy chart on a clipboard

The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...
Sjögren's disease diagnosis: close-up of a dry, irritated eye with eye drops being applied

Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis

Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...

Further News

Hyperfine Banks on $17.5 Million Public Stock Offering

Hyperfine Banks on $17.5 Million Public Stock Offering

Medical imaging company Hyperfine, listed on the Nasdaq as HYPR, has announced the pricing of an underwritten public offering of 14 million shares of its Class A common stock at $1.25 per share, yielding gross proceeds of approximately $17.5 million before...

read more
US Scientists Create Human Embryos from Skin Cells

US Scientists Create Human Embryos from Skin Cells

In a ground breaking advance in reproductive biology, researchers in the United States have for the first time created early-stage human embryos by converting DNA from skin cells into functional eggs and then fertilising them with sperm. Though still at an...

read more

Further News

Weekly News Roundup | 29 June 2026

Life science news 29 June 2026: AbbVie and Merck KGaA announce blockbuster acquisitions totalling more than $22 billion, NICE recommends the first disease-modifying therapy for type 1 diabetes for NHS use, and Definium Therapeutics delivers a landmark Phase 3 result...

Why I Founded Mesogen: A New Vision for Personalized Regenerative Medicine

For much of my career I have been fascinated by a simple but profound question: What if medicine could restore what disease destroys? Modern medicine has achieved remarkable success in helping patients manage chronic illnesses. We have developed sophisticated drugs,...

Light-Driven Immune Modulation and Its Impact on Autoimmune Therapy

One of the most consistent epidemiological patterns in multiple sclerosis (MS) is its geographic distribution. Rates rise with distance from the equator, where year-round sunlight exposure is lower.[1] For decades, this has pointed to a role for environmental light in...

Merck KGaA Acquires Bio-Techne for $11.3 Billion in Life Science Tools Deal

The Merck KGaA Bio-Techne acquisition values the Minneapolis-based life science tools company at approximately $11.3 billion. Merck KGaA, the German science and technology group, announced on 25 June 2026 that it will acquire Minneapolis-based Bio-Techne Corporation...

Clinical Trials Roundup | 26 June 2026

This week's clinical trial results for 26 June 2026 deliver a landmark psychiatric result, a major oncology setback, and a decisive blow to one of the most watched platforms in regenerative medicine. Definium Therapeutics' DT120 becomes the first lysergide therapy to...

The Role of the Microbiome in Topical Botanical Applications

The human skin is home to a complex and dynamic ecosystem of microorganisms collectively known as the skin microbiome. This microbial community - comprising bacteria, fungi, and viruses - plays a critical role in maintaining skin health, regulating immune responses,...

Beyond the Screen: Why Spinal Care Must Be Symptom-Led

In an era dominated by high-resolution diagnostics, the field of spinal care faces a profound paradox: while our ability to visualise cellular and structural anatomy has never been more advanced, the clinical efficacy of spinal interventions has not risen in tandem....

New Research Reveals How Toxic Proteins Kill Brain Cells in Dementia

Findings published in Nature Communications point to a previously uncharacterised cell death mechanism that could open new therapeutic targets for slowing neurodegeneration Researchers at King's College London and the UK Dementia Research Institute have identified a...

The ‘Wild West’ of Peptide Medicine and Who’s Qualified to Prescribe

In the medical field, being “authorized” and “qualified” are two very different things. Authorized generally indicates you have the legal right to practice. Qualified means you have the expertise, experience, and skill needed to practice effectively. The distinction...

Finding AF Before It Strikes: The Case for National Screening

There’s a concerning number of Australians living with a dangerous heart rhythm disorder - and many of them have no idea. Atrial fibrillation (AF) is a condition most people have never heard of and that’s a big problem, because it is already a silent cause of stroke. ...

Creative Biolabs Discusses Antibody Library Screening Workflow

Antibody library screening is widely used to identify antibody fragments, such as scFv, Fab, and single-domain antibodies, from large molecular repertoires. Compared with immunization-dependent approaches, library screening can be especially useful for challenging...

CAR-T Therapy Reaches Solid Tumours for the First Time

China's National Medical Products Administration (NMPA) approved satricabtagene autoleucel (satri-cel) on 22 June 2026, making it the world's first CAR-T cell therapy approved for a solid tumour. Developed by Shanghai-based CARsgen Therapeutics, satri-cel is cleared...

Want to Be Part of the Next Chapter in Life Sciences Media?

 

LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

 

 

Don’t wait for the media to pick up your story. Be the media.

Want to Be Part of the Next Chapter in Life Sciences Media?

 

LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

 

 

Don’t wait for the media to pick up your story. Be the media.